FDA recalls levothyroxine sodium tablets. Here's what to know - NBC 7 San Diego

What the report says

NBC 7 San Diego reported that the Food and Drug Administration has recalled certain levothyroxine sodium tablets, a thyroid medication commonly prescribed for people with hypothyroidism and also used to reduce enlarged thyroid glands. The report, published and updated July 27, 2026, said the affected products were distributed across the United States.

According to the NBC 7 summary of the FDA notice, the agency found the tablets to be “subpotent,” meaning they contained less active ingredient than expected and could be less effective for patients relying on consistent thyroid hormone replacement. Major Pharmaceuticals packaged and distributed the recalled tablets, while Cardinal Health distributed some of the products as well.

The FDA notice cited by NBC 7 listed 12 dosage and carton combinations tied to the recall. The article said the agency did not state how many tablets were involved. The recall was classified as Class II on July 13, a category the FDA uses when a product could cause temporary or medically reversible health effects, or when serious health consequences are considered unlikely.

The issue matters because levothyroxine dosing often requires close consistency, and reduced potency could affect thyroid hormone control. Patients who believe they may have affected medication should consult the FDA recall notice, check product details against the listed lots and packaging, and speak with a pharmacist or health care professional before making any medication changes.